A lesser-known medical device stock shows potential for a 20% increase, based on chart analysis.
Sector Performance: The health care sector, particularly medical devices, is showing signs of recovery, with the SPDR Health Care Select Sector ETF (XLV) and biotech stocks performing well, while Idexx Labs (IDXX) has reached all-time highs.
Stock Analysis: Steris (STE), a leader in sterilization and infection prevention, is highlighted as a strong investment opportunity, showing a favorable risk/reward setup with potential gains of 20%-25% as it breaks above key resistance levels.
Market Trends: The medical device sector is gaining traction, with Steris outperforming the sector average, indicating a rotation of investor interest towards this area.
Investment Advice: The content emphasizes the importance of setting risk parameters and suggests consulting a financial advisor before making investment decisions, as the information provided is general and not tailored to individual circumstances.
Trade with 70% Backtested Accuracy
Analyst Views on XLV
About the author
Investors Should Adopt a Defensive Strategy: Offload Staples and Invest in Healthcare.
- Investment Strategy: Investors are encouraged to shift their focus towards defensive stocks for better stability in uncertain markets.
- Sector Shift: The recommended approach is to sell off consumer staples and invest in the healthcare sector.
Three Previous Stock Selections Subtly Indicate Buy Opportunities Once More
- Market Opportunities: Investors may find renewed opportunities in previously recommended stocks from healthcare, oil services, and consumer staples sectors.
- Signs of Momentum: These stocks are showing signs of renewed momentum, suggesting potential upside for investors.
- Sector Rotation: The leadership in these sectors has already rotated, indicating a shift in market dynamics.
- Investor Consideration: Investors are encouraged to take a fresh look at these stocks as they may present attractive investment options.
Regencell Bioscience Leads Pharma Stocks in Year-to-Date Performance
S&P Healthcare Index Performance: The S&P healthcare index (XLV) achieved a year-to-date increase of 12.2% by mid-December 2025, ranking as the sixth-highest performing sector among the S&P 500 indexes.
Top Pharmaceutical Stocks: Regencell Bioscience (RGC) led the pharmaceutical sector with an extraordinary YTD performance of +15,138.46%, followed by Terns Pharmaceuticals (TERN) and Nuvation Bio (NUVB), which both received strong buy ratings.
Notable Stock Ratings: Nuvation Bio (NUVB) and Liquidia (LQDA) were highlighted for their strong buy ratings of 4.99 and 4.90, respectively, indicating strong investment potential.
Healthcare ETFs: Various healthcare ETFs, including XLV, VHT, and IHI, were mentioned as options for investors looking to gain exposure to the healthcare sector.
Market Update: Health Care Stocks Show Varied Performance Ahead of Thursday's Opening Bell
Health Care Stocks Performance: Health care stocks showed mixed results before the market opened on Thursday.
State Street Health Care Select Sector: The State Street Health Care Select Sector SPDR was mentioned in relation to the performance of health care stocks.
Industry Update: Healthcare Sector
Health Care Stocks Performance: Health care stocks experienced a decline on Monday afternoon, with the NYSE Health Care Index falling by 0.8%.
Market Impact: The decrease in health care stocks reflects broader market trends affecting investor sentiment in the sector.
Key Healthcare News This Week: Spotlight on Sanofi, Eli Lilly, and Novo Nordisk
U.S. Stock Market Performance: U.S. stocks saw a rally during the shortened trading week, with the S&P 500 up approximately 4%, the Dow also rising around 4%, and the Nasdaq Composite increasing by 5.5%. The S&P 500 Health Care Index Sector gained over 1.5%, with notable healthcare gainers including Moderna and Centene.
Trump's Stance on ACA Subsidies: President Trump expressed opposition to extending Affordable Care Act subsidies, stating he prefers not to extend them at all, while suggesting a shift towards individual payments for health insurance instead.
Medicare Drug Price Negotiations: The Trump administration negotiated significant price reductions for drugs like Ozempic and Wegovy under Medicare, achieving a 71% discount, which is expected to save taxpayers $12 billion, with the new prices set to take effect in 2027.
Sanofi's Tax Fraud Investigation: French authorities raided Sanofi's Paris headquarters as part of a tax fraud investigation linked to a financing arrangement with Societe Generale, with allegations of money laundering and criminal conspiracy being investigated.
Investors Should Adopt a Defensive Strategy: Offload Staples and Invest in Healthcare.
- Investment Strategy: Investors are encouraged to shift their focus towards defensive stocks for better stability in uncertain markets.
- Sector Shift: The recommended approach is to sell off consumer staples and invest in the healthcare sector.
Three Previous Stock Selections Subtly Indicate Buy Opportunities Once More
- Market Opportunities: Investors may find renewed opportunities in previously recommended stocks from healthcare, oil services, and consumer staples sectors.
- Signs of Momentum: These stocks are showing signs of renewed momentum, suggesting potential upside for investors.
- Sector Rotation: The leadership in these sectors has already rotated, indicating a shift in market dynamics.
- Investor Consideration: Investors are encouraged to take a fresh look at these stocks as they may present attractive investment options.
Regencell Bioscience Leads Pharma Stocks in Year-to-Date Performance
S&P Healthcare Index Performance: The S&P healthcare index (XLV) achieved a year-to-date increase of 12.2% by mid-December 2025, ranking as the sixth-highest performing sector among the S&P 500 indexes.
Top Pharmaceutical Stocks: Regencell Bioscience (RGC) led the pharmaceutical sector with an extraordinary YTD performance of +15,138.46%, followed by Terns Pharmaceuticals (TERN) and Nuvation Bio (NUVB), which both received strong buy ratings.
Notable Stock Ratings: Nuvation Bio (NUVB) and Liquidia (LQDA) were highlighted for their strong buy ratings of 4.99 and 4.90, respectively, indicating strong investment potential.
Healthcare ETFs: Various healthcare ETFs, including XLV, VHT, and IHI, were mentioned as options for investors looking to gain exposure to the healthcare sector.
Market Update: Health Care Stocks Show Varied Performance Ahead of Thursday's Opening Bell
Health Care Stocks Performance: Health care stocks showed mixed results before the market opened on Thursday.
State Street Health Care Select Sector: The State Street Health Care Select Sector SPDR was mentioned in relation to the performance of health care stocks.
Industry Update: Healthcare Sector
Health Care Stocks Performance: Health care stocks experienced a decline on Monday afternoon, with the NYSE Health Care Index falling by 0.8%.
Market Impact: The decrease in health care stocks reflects broader market trends affecting investor sentiment in the sector.
Key Healthcare News This Week: Spotlight on Sanofi, Eli Lilly, and Novo Nordisk
U.S. Stock Market Performance: U.S. stocks saw a rally during the shortened trading week, with the S&P 500 up approximately 4%, the Dow also rising around 4%, and the Nasdaq Composite increasing by 5.5%. The S&P 500 Health Care Index Sector gained over 1.5%, with notable healthcare gainers including Moderna and Centene.
Trump's Stance on ACA Subsidies: President Trump expressed opposition to extending Affordable Care Act subsidies, stating he prefers not to extend them at all, while suggesting a shift towards individual payments for health insurance instead.
Medicare Drug Price Negotiations: The Trump administration negotiated significant price reductions for drugs like Ozempic and Wegovy under Medicare, achieving a 71% discount, which is expected to save taxpayers $12 billion, with the new prices set to take effect in 2027.
Sanofi's Tax Fraud Investigation: French authorities raided Sanofi's Paris headquarters as part of a tax fraud investigation linked to a financing arrangement with Societe Generale, with allegations of money laundering and criminal conspiracy being investigated.
